Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

The efficacy of clarithromycin and the bicyclolide EDP-420 against Mycobacterium avium in a mouse model of pulmonary infection.

Bermudez LE, Motamedi N, Kolonoski P, Chee C, Baimukanova G, Bildfell R, Wang G, Phan LT, Lowell SY.

J Infect Dis. 2008 Jun 1;197(11):1506-10. doi: 10.1086/587906.

2.

EDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium.

Bermudez LE, Motamedi N, Chee C, Baimukanova G, Kolonoski P, Inderlied C, Aralar P, Wang G, Phan LT, Young LS.

Antimicrob Agents Chemother. 2007 May;51(5):1666-70. Epub 2007 Feb 12.

3.

[Therapeutic efficacy of macrolide in pulmonary nontuberculous mycobacteriosis].

Tomono K.

Kekkaku. 1994 Nov;69(11):725-32. Japanese.

PMID:
7837727
4.

Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy.

Bermudez LE, Petrofsky M, Kolonoski P, Young LS.

Antimicrob Agents Chemother. 1998 Jan;42(1):180-3.

5.

Clarithromycin, dapsone, and a combination of both used to treat or prevent disseminated Mycobacterium avium infection in beige mice.

Bermudez LE, Inderlied CB, Kolonoski P, Petrofsky M, Young LS.

Antimicrob Agents Chemother. 1994 Dec;38(12):2717-21.

7.
8.

Effect of ethambutol on emergence of clarithromycin-resistant Mycobacterium avium complex in the beige mouse model.

Bermudez LE, Nash KA, Petrofsky M, Young LS, Inderlied CB.

J Infect Dis. 1996 Dec;174(6):1218-22.

9.

[Clinical study on development of nontuberculous mycobacterial lung disease].

Kurashima A.

Kekkaku. 2004 Dec;79(12):737-41. Review. Japanese.

PMID:
15782619
10.

Early pulmonary resection for Mycobacterium avium complex lung disease treated with macrolides and quinolones.

Watanabe M, Hasegawa N, Ishizaka A, Asakura K, Izumi Y, Eguchi K, Kawamura M, Horinouchi H, Kobayashi K.

Ann Thorac Surg. 2006 Jun;81(6):2026-30.

PMID:
16731124
11.

Mycobacterium avium complex pulmonary disease: management options in HIV-negative patients.

Ramirez J, Mason C, Ali J, Lopez FA.

J La State Med Soc. 2008 Sep-Oct;160(5):248-54; quiz 254, 293.

PMID:
19048978
12.

Targeted drug delivery to enhance efficacy and shorten treatment duration in disseminated Mycobacterium avium infection in mice.

de Steenwinkel JE, van Vianen W, Ten Kate MT, Verbrugh HA, van Agtmael MA, Schiffelers RM, Bakker-Woudenberg IA.

J Antimicrob Chemother. 2007 Nov;60(5):1064-73. Epub 2007 Sep 10.

13.

Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo.

Koga T, Fukuoka T, Doi N, Harasaki T, Inoue H, Hotoda H, Kakuta M, Muramatsu Y, Yamamura N, Hoshi M, Hirota T.

J Antimicrob Chemother. 2004 Oct;54(4):755-60. Epub 2004 Sep 3.

14.
15.

Comparative activities of azithromycin and clarithromycin against Mycobacterium avium infection in beige mice.

Cynamon MH, Klemens SP, Grossi MA.

Antimicrob Agents Chemother. 1994 Jul;38(7):1452-4.

16.

Comparative in vivo activities of rifabutin and rifapentine against Mycobacterium avium complex.

Klemens SP, Grossi MA, Cynamon MH.

Antimicrob Agents Chemother. 1994 Feb;38(2):234-7.

17.

[The clinical study of clarithromycin for pulmonary Mycobacterium avium-intracellulare complex infection].

Yamamoto M, Kuze F, Sakatani M, Saito H, Shimoide H, Soejima R, Hara K.

Kekkaku. 1997 Jan;72(1):1-7. Japanese.

PMID:
9038009
18.
20.
Items per page

Supplemental Content

Write to the Help Desk